- Home
- CHY vs BBNX Comparison
CHY vs BBNX Comparison
Compare CHY & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHY
- BBNX
- Stock Information
- Founded
- CHY 2003
- BBNX 2015
- Country
- CHY United States
- BBNX United States
- Employees
- CHY N/A
- BBNX N/A
- Industry
- CHY Investment Managers
- BBNX Medical/Dental Instruments
- Sector
- CHY Finance
- BBNX Health Care
- Exchange
- CHY Nasdaq
- BBNX Nasdaq
- Market Cap
- CHY 792.1M
- BBNX 841.5M
- IPO Year
- CHY N/A
- BBNX 2025
- Fundamental
- Price
- CHY $10.52
- BBNX $17.89
- Analyst Decision
- CHY
- BBNX Strong Buy
- Analyst Count
- CHY 0
- BBNX 10
- Target Price
- CHY N/A
- BBNX $25.20
- AVG Volume (30 Days)
- CHY 128.3K
- BBNX 504.1K
- Earning Date
- CHY 01-01-0001
- BBNX 08-06-2025
- Dividend Yield
- CHY 10.11%
- BBNX N/A
- EPS Growth
- CHY N/A
- BBNX N/A
- EPS
- CHY N/A
- BBNX N/A
- Revenue
- CHY N/A
- BBNX $69,830,000.00
- Revenue This Year
- CHY N/A
- BBNX $32.79
- Revenue Next Year
- CHY N/A
- BBNX $36.59
- P/E Ratio
- CHY N/A
- BBNX N/A
- Revenue Growth
- CHY N/A
- BBNX 38911.17
- 52 Week Low
- CHY $9.97
- BBNX $8.89
- 52 Week High
- CHY $12.16
- BBNX $24.50
- Technical
- Relative Strength Index (RSI)
- CHY 53.00
- BBNX N/A
- Support Level
- CHY $10.46
- BBNX N/A
- Resistance Level
- CHY $10.79
- BBNX N/A
- Average True Range (ATR)
- CHY 0.10
- BBNX 0.00
- MACD
- CHY -0.02
- BBNX 0.00
- Stochastic Oscillator
- CHY 42.55
- BBNX 0.00
About CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.
About BBNX Beta Bionics Inc. Common Stock
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.